Add to ORKGCopyright © 2013 Stephan W. Hirt et al.This is an open access article distributed under theCreative CommonsAttribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The evidence base relating to the use of everolimus in heart transplantation has expanded considerably in recent years, providing clinically relevant information regarding its use in clinical practice. Unless there are special considerations to take into account, all de novo heart transplant patients can be regarded as potential candidates for immunosuppression with everolimus and reduced
The role of everolimus in cardiac transplantation is being increasingly recognized.Multiple studies ...
Although everolimus potentially improves long-term heart transplantation (HTx) outcomes, its early p...
Everolimus is a proliferation signal inhibitor (PSI)/ mammalian target of rapamycin inhibitor that i...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The efficacy of everolimus with reduced cyclosporine in de novo heart transplant patients has been d...
OBJECTIVES: We examined the experiences of heart transplant recipients receiving everolimus as maint...
Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomize...
Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to p...
Everolimus is licensed for the prevention of acute rejection in heart or kidney transplant recipient...
Abstract: BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may s...
As the risk of graft loss due to acute rejection has declined, the goal of post-transplant managemen...
Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibito...
Background. Tacrolimus (Tac) in combination with mycophenolate mofetil is widely used after heart tr...
The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a c...
The role of everolimus in cardiac transplantation is being increasingly recognized.Multiple studies ...
Although everolimus potentially improves long-term heart transplantation (HTx) outcomes, its early p...
Everolimus is a proliferation signal inhibitor (PSI)/ mammalian target of rapamycin inhibitor that i...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The evidence base relating to the use of everolimus in heart transplantation has expanded considerab...
The efficacy of everolimus with reduced cyclosporine in de novo heart transplant patients has been d...
OBJECTIVES: We examined the experiences of heart transplant recipients receiving everolimus as maint...
Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomize...
Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to p...
Everolimus is licensed for the prevention of acute rejection in heart or kidney transplant recipient...
Abstract: BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may s...
As the risk of graft loss due to acute rejection has declined, the goal of post-transplant managemen...
Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibito...
Background. Tacrolimus (Tac) in combination with mycophenolate mofetil is widely used after heart tr...
The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a c...
The role of everolimus in cardiac transplantation is being increasingly recognized.Multiple studies ...
Although everolimus potentially improves long-term heart transplantation (HTx) outcomes, its early p...
Everolimus is a proliferation signal inhibitor (PSI)/ mammalian target of rapamycin inhibitor that i...